U.S. Biosimilars: The "Devil's In The Details," Sandoz Chief Says
Regulatory pathways like 505(b)(2) and BLA, not the new one created through health care legislation, may be best for biosimilars, Sandoz CEO George says.
Regulatory pathways like 505(b)(2) and BLA, not the new one created through health care legislation, may be best for biosimilars, Sandoz CEO George says.